DIGNITY Trial for RCW Breast Cancer

  • Share
    Share Video

  • Add
  • More
    Report this video as:
0 0
You have already voted for this video.
Celsion Corporation (NASDAQ:CLSN) announced today initiation of a nationwide enrollment program in its pivo...
Celsion Corporation (NASDAQ:CLSN) announced today initiation of a nationwide enrollment program in its pivotal Phase I/II DIGNITY clinical trial evaluating the use of ThermoDox® in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer. In early studies, conducted at Duke University Medical Center, investigators report that ThermoDox® has demonstrated significant promise in treating this highly aggressive disease. To view Multimedia News Release, go to http://www2.prnewswire.com/mnr/celsion/39944/
Categories:
Related